Genetic variability in CYP3A5 and its possible consequences

被引:242
作者
Xie, HG
Wood, AJJ
Kim, RB
Stein, CM
Wilkinson, GR
机构
[1] Vanderbilt Univ, Sch Med, Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Pharmacol, Div Clin Pharmacol, Nashville, TN 37232 USA
关键词
CYP3A4; CYP3A5; ethnic diversity; molecular genetic; epidemiology; pharmacogenetics; pharmacogenomics polymorph ism; population genetics;
D O I
10.1517/phgs.5.3.243.29833
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The cytochrome P450 3A (CYP3A) subfamily members are the most abundant and important drug-metabolizing enzymes in humans, and wide interindividual variability in CYP3A expression and function is present. CYP3A4 alone cannot fully explain the observed constitutive variability because its genetic variants are relatively uncommon and have limited functional significance, whereas CYP3A5 expression in humans is highly variable and may be contributory. However, it is difficult to delineate the relative contribution of CYP3A4 and CYP3A5, and to differentiate their effects on drug metabolism as their protein structure, function and substrates are so similar. By contrast, molecular biology methods provide the ability to identify CYP3A4 and CYP3A5 genotypes with certainty. This review collates currently available data on CYP3A5 polymorphisms, provides information on the population frequency of each genetic variant in major ethnic groups, and describes in vitro and in vivo studies that have attempted to identify genotype-phenotype associations.
引用
收藏
页码:243 / 272
页数:30
相关论文
共 164 条
[1]   ETHNIC-DIFFERENCES IN THE PHARMACOKINETICS OF ORAL NIFEDIPINE [J].
AHSAN, CH ;
RENWICK, AG ;
MACKLIN, B ;
CHALLENOR, VF ;
WALLER, DG ;
GEORGE, CF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (04) :399-403
[2]   THE INFLUENCES OF DOSE AND ETHNIC-ORIGINS ON THE PHARMACOKINETICS OF NIFEDIPINE [J].
AHSAN, CH ;
RENWICK, AG ;
WALLER, DG ;
CHALLENOR, VF ;
GEORGE, CF ;
AMANULLAH, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (03) :329-338
[3]   Racial variation in dosage requirements of tacrolimus [J].
Andrews, PA ;
Sen, M ;
Chang, RWS .
LANCET, 1996, 348 (9039) :1446-1446
[4]  
[Anonymous], 1994, Adv Drug Res
[5]   Expression and localization of CYP3A4 and CYP3A5 in human lung [J].
Anttila, S ;
Hukkanen, J ;
Hakkola, J ;
Stjernvall, T ;
Beaune, P ;
Edwards, RJ ;
Boobis, AR ;
Pelkonen, O ;
Raunio, H .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1997, 16 (03) :242-249
[6]  
AOYAMA T, 1989, J BIOL CHEM, V264, P10388
[7]   CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia [J].
Aplenc, R ;
Glatfelter, W ;
Han, P ;
Rappaport, E ;
La, M ;
Cnaan, A ;
Blackwood, MA ;
Lange, B ;
Rebbeck, T .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (02) :240-244
[8]   The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin [J].
Backman, JT ;
Kivistö, KT ;
Olkkola, KT ;
Neuvonen, PJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (01) :53-58
[9]   Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4 [J].
Ball, SE ;
Scatina, JA ;
Kao, J ;
Ferron, GM ;
Fruncillo, R ;
Mayer, P ;
Weinryb, I ;
Guida, M ;
Hopkins, PJ ;
Warner, N ;
Hall, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (03) :288-294
[10]   CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations [J].
Balram, C ;
Zhou, QY ;
Cheung, YB ;
Lee, EJD .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (02) :123-126